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p73, a new candidate tumour suppressor gene, was recently identi-
fied at 1p36, the short arm of chromosome 1, by Kaghad et al
(1997). The homology between p73 and p53 is extensive within
most conserved p53 domains (Zambetti et al, 1993; Ko et al, 1996;
Kaghad et al, 1997). Wild p53 works as a so-called security guard
to induce cell cycle arrest or apoptosis in response to cellular
stresses on DNA damage (Livingstone et al, 1992; Lowe et al,
1993; Dickman, 1997), and loss or inactivation of p53 is thought
to contribute to the development of 50% of all human cancers
(Levine, 1997). Therefore, according to the known homology
between p53 and p73, p73 is also expected to work as a tumour
suppressor gene. Deletions of 1p36 are common in neuroblas-
tomas, and extremely low level of p73 mRNA have been found in
the majority of neuroblastoma cell lines (Caron et al, 1995;
Kaghard et al, 1997), showing that, at least in neuroblastoma, p73
apparently works as a tumour supprressor gene in spite of the lack
of definitive evidence.
However, very recently Mai et al (1998) reported that p73 might
be overexpressed in lung cancer tissues in comparison with normal
lung. Furthermore, p73 genomic mutation has not been found even
after intensive research (Mai et al, 1998; Nomoto et al, 1998;
Takahashi et al, 1998). Accordingly, it is questionable whether p73
works as a tumour suppressor gene in lung cancer. To verify the
role of p73 in lung carcinogenesis, we measured the amount of p73
mRNA expression in 86 primary lung cancer tissues and paired
normal lung tissues by semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR). We then analysed the
relationship between the amount of p73 expression and clinico-
pathological characteristics. Moreover, we examined for p53 gene
alteration to clarify the relationship between p73 mRNA expres-
sion and p53 gene status.
MATERIALS AND METHODS
Materials and histological classification
Surgically resected tumours and paired corresponding normal
tissues were obtained from 86 patients with primary lung cancers
at the Cancer Institute Hospital (Tokyo, Japan), from 1990 to
1993. All samples were quickly frozen in liquid nitrogen and
stored at –80°C until RNA was extracted. RNA was estimated
by b-actin mRNA expression amplified with RT-PCR, and we
excluded 26 cases because of the poor quality of the extracted
RNA. Distribution of histological types of the 60 lung cancers
were: 34 adenocarcinomas, 19 squamous cell carcinomas, three
large-cell carcinomas, two small-cell carcinomas and two
adenosquamous carcinomas (World Health Organization, 1981)
(Table 1). The median age of the 60 patients was 61 years (range
44–80 years). Forty-five of the 60 patients were men, and all 15
female patients had adenocarcinoma. The stage of each tumour
was determined according to the TNM Classification of Malignant
Tumours defined by the International Union Against Cancer
(UICC, 1992): 19 stage I, 11 stage II, 21 stage IIIA, eight stage
IIIB and one stage IV. To evaluate the consumption of cigarettes
smoked before lung cancer diagnosis, a smoking index was used:
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Table 1 The relationship among characteristics of the patients, the amount of p73 expression and p53 gene status
No. Sex Age Histologya p-Stage Smoking indexb p73 in normal tissuesc p73 in tumour p53 gene statusd Exon Codon Base change
48 M 72 Ad II 750 0.95 6.41 ND
52 M 65 Sq IIIA 900 1.78 27.88 ND
54 M 70 Sq IIIB 1250 2.54 6.14 Mutant 5 149–175 deletion 74b
55 M 59 AS I 740 1.43 10.81 ND
57 M 66 L IIIB 1600 0.30 1.69 ND
60 M 68 Sq IIIA 940 0.34 8.14 Wild
62 M 80 Sq II 840 1.35 20.08 Wild
63 M 76 Sm IIIA 1250 4.08 58.06 ND
64 M 54 Sq IIIB 1350 1.04 3.93 Wild
65 M 60 Ad IIIA 800 0.28 0.84 Wild
66 W 51 Ad IIIB 0 0.41 0.42 Mutant 7 245 GGC-AGC
68 W 44 Ad IIIB 0 0.69 1.58 Wild
69 M 58 Ad IIIA 1600 0.78 3.97 Mutant 8 273 CGT-TGT
70 M 59 Sq IIIA 1200 0.72 9.62 Mutant 5 175 CGC-CAC
85 M 58 Sq IIIA 1330 3.31 1.45 ND
87 M 65 Sq I 760 6.94 10.14 Mutant 7 244 GGC-TGC
91 M 65 Ad I 2280 0.03 1.47 Wild
93 W 61 Ad I 310 0.42 2.44 Wild
94 M 78 Sq I 1020 0.78 29.20 Wild
97 M 54 Ad IIIA 960 0.22 0.48 Mutant 6 198 GAA-TAA
98 M 67 Sm IIIA 940 0.05 1.88 ND
99 M 70 Sq I 1520 0.37 5.85 Wild
101 W 68 Ad IIIA 75 2.47 12.32 Mutant 7 242 TGC-TAC
102 M 53 Sq I 234 0.24 2.12 Wild
106 M 51 AS IIIA 0 0.30 2.05 ND
111 M 54 Ad I 540 3.00 13.26 Wild
114 W 77 Ad I 0 0.70 2.72 Wild
117 W 59 Ad IIIA 0 1.51 5.33 Wild
121 M 64 Ad II 1320 0.38 3.32 Wild
122 W 74 Ad IIIA 240 0.88 3.33 Mutant 6 209 AGA-TGA
126 M 66 L IIIA 460 0.53 4.63 ND
127 M 44 Ad I 340 0.06 0.66 Wild
130 W 55 Ad I 0 0.10 0.06 ND
135 M 49 Sq IIIA 300 0.46 4.02 Mutant 6 196 CGA-CCA
136 M 50 Ad I 1600 0.30 6.51 Wild
137 M 68 Ad IIIA 0 0.11 0.35 Wild
141 M 59 Sq I 780 0.53 1.45 Wild
142 M 70 Ad I 561 0.55 2.79 Wild
143 M 54 Ad IIIA 1440 3.18 12.21 Wild
146 M 76 Sq II 1250 1.51 15.88 Mutant 5 144 CAG-CCG
147 W 68 Ad I 0 0.40 0.19 Wild
150 M 63 Ad IV 600 0.17 0.54 Wild
153 W 50 Ad II 0 1.00 1.06 Wild
157 M 49 Ad II 20 1.21 2.16 Mutant 7 238 TGT-AGT
159 M 51 Sq II 1240 0.12 5.64 Mutant 10 5 junction agAT-tgAT
160 M 50 Ad IIIB 2310 0.62 3.23 Mutant 6 189 CCC-G_C
168 W 51 Ad II 0 0.88 3.62 Wild
174 M 72 Ad I 510 2.00 2.59 Mutant 8 273 CGT-CAT
178 M 50 Ad I 1750 0.61 4.89 Wild
179 M 70 Sq IIIA 1590 2.27 9.40 Mutant 6 195 ATC-ACC
188 M 53 Sq II 1320 0.90 4.77 Mutant 8 271 GAG-TAG
193 M 68 Sq IIIA 1440 1.33 12.47 Mutant 7 245 GGC-GTC
196 M 61 Ad II 3680 1.20 3.74 Wild
200 M 71 Sq IIIB 1020 1.56 5.65 Mutant 4 103 TAC-TAG
201 W 51 Ad I 0 0.10 2.44 Wild
202 W 70 Ad IIIA 0 0.65 4.13 Wild
203 W 67 Ad IIIB 0 0.74 5.65 Mutant 5 132 AAG-AGG
205 W 49 Ad I 0 0.44 1.39 Mutant 6 213 CGA-TGA
206 M 49 L II 1015 2.18 15.74 ND
208 M 71 Ad IIIA 960 1.72 10.75 Mutant 5 157 GTC-TTC
aAd, Adenocarcinoma; Sq, Squamous cell carcinoma; Sm, Small cell carcinoma; L, Large cell carcinoma; AS, Adenosquamous carcinoma. bSmoking index is
defined as cigarette consumption per day multiplied by smoking years. cp73 expression is estimated by dividing by b-actin expression. dND, not done.cigarette consumption per day multiplied by smoking years. Heavy
smokers were defined as those with smoking indices over 400.
Preparation of RNA and expression of p73 mRNA using
RT-PCR
All tissue samples were frozen in liquid nitrogen immediately after
surgery and subjected to isolation of RNA as previously reported
(Tokuchi et al, 1999). RNAs were prepared from 0.1–0.2 g of
human primary lung cancers and paired non-cancerous
parenchyma according to the method of Chomczynski and Sacchi
(1987), which was quantified using UV spectrometry at 260 nm.
The RNAs (1.0 mg) in a 40 ml reaction volume were reverse tran-
scribed to synthesize cDNA using Takara RNA PCR kit (Takara,
Tokyo) with 2.5-mM random hexamers at 42°C. The oligo-
nucleotides used in PCR amplification were as follows: P1 (sense
strand in exons 4 and 5 of the p73 gene), GAC GTA CTC CCC
GCT CTT GA; P2 (antisense strand in exon 7 of the p73 gene),
TGG CTC ATA GGG CAC CAC GA; P3 (sense strand in exon
7 of the p73 gene), ATT CAC CAC CAT CCT GTA CA; P4
(antisense strand in exon 9 of the p73 gene), GCT GCT GCT GCT
GCC GAT AG; P5 (sense strand of the b-actin), CAA GAG ATG
GCC ACG GCT GCT; P6 (antisense strand of the b-actin), TCC
TTC TGC ATC CTG TCG GCA. PCR amplification of the p73
cDNA was performed using 1 ml of the cDNA, 0.2-mM primers
P1 and P2 in 25-ml mixtures consisting of 1 U Taq DNA poly-
merase (Boehringer Mannheim), 0.05 MegaBequerel (MBq) of
[a-32P]dCTP, 10 mM Tris–HCI (pH 8.3), 50 mM potassium
chloride, 1.5 mM magnesium chloride and 40 mM deoxynucleotide
triphosphates (dATP, dTTP, dGTP and dCTP). The PCR reaction
comprised 35 cycles with denaturing at 95°C for 30 s, and
annealing and extension at 72°C for 20 s in each cycle, using a
GeneAmp PCR System 9600 (Perkin-Elmer Corp.). Ten
microlitres of the amplified product was subjected to 5% polyacry-
lamide gel electrophoresis, and the radioactivity was evaluated
with Bio-Image analyser BAS2000 (Fuji Film, Tokyo). The PCR
product size using P1 and P2 is 301 bases; using P3 and P4, 439
bases. No expected PCR products were observed when RT was not
performed. To confirm the results with P1 and P2, an additional
PCR using P3 and P4 was also performed: it comprised 40 cycles
using a GeneAmp PCR System 9600 (Perkin-Elmer Corp.) in the
buffer described above, with denaturing at 95°C for 30 s, and
annealing and extension at 70°C for 1 min in each cycle.
As a control for RNA quality, separate portions of cDNA were
amplified using primers specific for human b-actin. PCR was
performed using 1 ml of cDNA, 1 U Taq DNA polymerase
(Boehringer Mannheim), 0.5 mM P5 and P6, 0.05 MBq of [a-32P]-
dCTP and 0.15 mM magnesium chloride in 25-ml incubation
buffers. The reaction (95°C and 63°C for 30 s, and 72°C for 1 min)
was performed for 21 cycles.
To quantify the amount of PCR products of p73 (using P1 and
P2) and b-actin, 18 matched samples of lung tumours and normal
lung tissues were processed simultaneously, and the radioactivity
was determined with BAS2000 (Fuji Film, Tokyo, Japan). The
amount of PCR product of each sample was expressed as a value
relative to the average radioactivity of 18 normal lungs in each
assay. Each PCR and electrophoresis procedure was repeated
twice, after which we calculated the average p73 and b-actin
expression for each sample. Finally, we arrived at the relative
p73:b-actin ratio, calculated by dividing the average amount of
p73 by that of b-actin, for each sample.
p73 genomic-Southern blot hybridization
Genomic DNAs from tumours and paired normal lung tissues of
three representatives cases were extracted using standard methods
as previously reported (Tsuchiya et al, 1992; Tokuchi et al, 1999).
After each 10-mg DNA were completely digested with HindIII,
DNAs were subjected to 0.8% agarose gel electrophoresis. Using
vacuum blotter (Bio-Rad), DNA samples were rapidly transferred
to the nylon membrane (Hybond-N; Amersham Japan, Tokyo,
Japan) in 10 ´ standard saline citrate (SSC), and then cross-linked
under UV light. RT-PCR products amplified with P1 and P2
primers, which contained exon 5, 6 and a part of exon 7 of p73
coding sequence, were cut from the gel and purified using 0.45-mm
centrifugal filter (Millipore), phenol–chloroform extraction and
subsequent ethanol precipitation. After this, the purified DNAs
were radiolabelled with [a-32P]dCTP and multiprime DNA
labelling systems kit (RPN. 1601Y, Amersham). Southern blot
hybridization was performed at 59°C in 5 ´ SSC, 10 ´ Denhard’s
solution, 10 mM EDTA, 200 mg ml–1 salmon sperm DNA and 1%
sodium dodecyl sulphate (Sambrook et al, 1989). After sufficient
washing, the radioactivity was evaluated with Bio-Image analyser
BAS2000 (Fuji Film, Tokyo, Japan).
p53 mutation analysis and DNA sequencing
In 49 of the 53 patients with adenocarcinoma or squamous cell
carcinoma, genomic DNAs were obtained and examined for p53
alterations (exons 4–8 and 10) using PCR-single-strand conforma-
tion polymorphism (PCR-SSCP) (Kishimoto et al, 1992).
Sequences of oligonucleotides used in PCR were as follows: exon
4 of p53, the sense primer, 5¢-ACC TGG TCC TCT GAC TGC
TCT TTT CA and the antisense primer, 5¢-CCA GGC ATT GAA
GTC TCA TGG AAG C; exon 5, 5¢-TCT GTT CAC TTG TGC
CCT GA and 5¢-GCC AGA CCT AAG AGC AAT CA; exon 6, 5¢-
GCT GGG GCT GGA GAG ACG AC and 5¢-GAC AAC CAC
CCT TAA CCC CT; exon 7, 5¢-CTT GCC ACA GGT CTC CCC
AA and 5¢-GGT CAG CGG CAA GCA GAG GC; expn 8, 5¢-TTA
AAT GGG ACA GGT AGG AC and 5¢-GAT AAA AGT GAA
TCT GAG GCA T; exon 10, 5¢-TAT ACT TAC TTC TCC CCC
TCC TCT and 5¢-ATG AGA ATG GAA TCC TAT GGC TTT. The
5¢-end of each primer was labelled with fluorescence: sense
primer, 6-carboxyfluorescein, and antisense primer, 4,7,2¢,7¢-
tetrachloro-6-carboxyfluorescein (Japan Bio Service Corp., Asaka,
Japan). Genomic DNAs were extracted from 49 tumours and
paired normal lung tissues (Tokuchi et al, 1999), and subjected to
PCR reaction mixture containing 50 ng genomic DNA, 10 pM each
pair of primers, 0.2 mM deoxynucleotide triphosphates (dATP,
dTTP, dGTP and dCTP), 1.0 U Taq DNA polymerase (Boehringer
Mannheim), 10 mM Tris–HCl (pH 8.3), 50 mM potassium chloride
and 1.5 mM magnesium chloride. After initial denaturation (for 2
min at 94°C), 30 cycles PCR were carried out as follows: 94°C for
30 s, adequate annealing temperature for 30 s (exon 4, 69°C; exon
5, 53°C; exon 6, 63°C; exon 7, 64°C; exon 8, 59°C; and exon 10,
63°C) and 72°C for 30 s in a GeneAmp PCR System 9600 (Perkin-
Elmer Corp.). PCR products were denatured at 98°C for 5 min,
applied to 4% non-denaturing polyacrylamide gel with 10%
glycerol, and electrophoresed at 22°C using ABI PRISMTM 377
(Perkin-Elmer Corp.). SSCP data were processed by GeneScan
Analysis 2.0.2 computer software (Perkin-Elmer Corp.). Where
genomic DNAs extracted from tumours showed different SSCP
patterns from corresponding normal lung tissues, both genomic
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[a-32P]dCTP to elute the shifted DNA fragments for sequence
analysis. After PCR in the same cycle condition, PCR products
were electrophoresed in a 5% non-denaturing polyacrylamide gel
with 10% glycerol at the most suitable temperature (exon 4, 10°C;
exon 5–7 and 10, 25°C; exon 8, 15°C). After the gel was vacuum-
dried and exposed to X-ray film, both normal and abnormal DNA
fragments were eluted from the dried gel. Next, eluted DNAs were
reamplified by PCR using the same primers, and the reamplified
DNAs were sequenced using the dRhodamine terminator cycle
sequencing kit (Applied Biosystems Inc.) and ABI PRISMTM 377
(Perkin-Elmer Corp.).
Statistical analysis
All data were analysed using the Statistical Package for Social
Sciences (SPSS), and a comparison of relative p73:b-actin expres-
sion ratios in tumours and in normal lung tissues was carried out
using the Mann–Whitney U-test. The association between relative
p73:b-actin expression ratio and clinicopathological parameters
(age, sex, smoking habits, histological types and pathological
staging) was estimated in 53 adenocarcinomas and squamous cell
carcinomas, using the Mann–Whitney U-test and the Spearman
rank correlation method. When any parameters significantly corre-
lated with relative p73 expression, we used the partial correlation
analysis to exclude the interaction among these parameters. Linear
regression was used to test the association between p73:b-actin
expression ratio and clinical characteristics; the optimal regression
model was chosen using the backward step-wise selection of
variables. Moreover, relative p73:b-actin expression ratio
was compared with p53 gene alteration in 49 of the above 53
adenocarcinomas and squamous cell carcinomas using the
Mann–Whitney U-test. All P-values < 0.05 were considered
significant.
RESULTS
To check the linear relationship between amount of RNA and
radiolabelled PCR products in the semi-quantitative RT-PCR
method, various amounts of total RNA were processed by RT-PCR
amplification. The mean value of the duplicate p73 PCR products
amplified by using P1 and P2 increased dose-dependently at 35
cycles of amplification (Figure 1A), and a similar relationship
between b-actin PCR products and amounts of RNA was also
observed (Figure 1B).
Figure 2 shows the representative p73 RT-PCR products from
paired normal lungs and tumours, in which increased p73 expres-
sion was observed in tumours compared with normal lung tissues.
Use of another set of primers, P3 and P4, confirmed the results of
PCR using P1 and P2 (data not shown). In 87% of the cases
(52/60), the relative p73:b-actin ratio in tumours is more than
twice as high as that in normal tissues, but the reverse is found in
only 5% of the cases (3/60, No 85, 130 and 147 in Table 1).
Distribution of the relative p53:b-actin ratio both in normal lung
tissues and in tumours in shown in Figure 3. The expression of p73
mRNA in lung tumours is distributed significantly higher than that
in normal lungs (P < 0.0001, Mann–Whitney U-test); the means
amounts of p73 mRNA in lung tumours and normal tissues were
6.76 and 1.10 respectively.
In order to examine whether the overexpression of p73 exclu-
sively observed in lung tumours was due to the gene amplification,
Southern blot analysis was performed using genomic DNAs.
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Figure 1 Demonstration of relative radioactivity of p73 (A) and b-actin (B) mRNA RT-PCR products. Various amounts of RNA of the tumour (case No. 101) in
20-ml reaction buffer were reverse-transcribed (lane 1, 0.0625 mg; lane 2, 0.125 mg; lane 3, 0.25 mg; lane 4, 0.5 mg), and each 1 ml cDNA was amplified with
radiolabelled dCTP by PCR with P1 and P2, and with P5 and P6, as described in Materials and Methods. The dots on the graphs are the means of duplicate
examinationsGenomic DNAs were extracted from three representative cases in
which p73 mRNA expression was markedly higher in tumours
than in normal tissues: none of these cases showed the amplifica-
tion of p73 gene (Figure 4), thus eliminating amplification as the
cause of p73 overexpression in these three cases.
Next, we analysed the relationship between the relative
p73:b-actin ratio and the clinicopatholigical features in 53 lung
adenocarcinomas and squamous cell carcinomas, using the
Mann–Whitney  U-test and the Spearman rank correlation. The
relative p73:b-actin ratios in tumours were found to significantly
correlate with differences of histology (adenocarcinoma or squa-
mous cell carcinoma), age, sex and smoking index (Tables 2 and
3). However, we could not ignore inter-relationships within these
parameters, so we applied the partial correlation analysis. We
found that only differences in histology and age significantly
correlated with the relative p73:b-actin ratio independently of
other factors (Table 4). This result was reconfirmed by the optimal
multivariate linear regression model with the backward step-wise
selection of variables: the final model obtained after the steps
included age and histological types only as significant and
independent variables.
Concerning the comparison of p73 expression in normal lung
tissues and clinicopathological parameters, the relative p73:b-actin
expression ratio in normal tissues is significantly associated
with the age of the patients and p73 expression in paired tumours
(P<0.05 respectively, the Spearman rank correlation). Accord-
ingly, the relative p73:b-actin expression ratio in normal tissues
also increases with age, although it is far lower than in
tumours.
We also examined mutational status of p53 gene in 92% of the
cases (49/53) with adenocarcinomas or squamous cell carcinomas
p73 overexpression in lung cancer 1627
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Figure 2 Representative autoradiogram of RT-PCR products of p73 (A)
and b-actin (B) mRNA in lung cancer and normal tissue. T, lung cancer
tissue; L, paired normal lung tissue. (A) p73 expression amplified with P1
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Figure 3 Distribution of the relative p73; b-actin expression ratio in 60
paired normal lung tissues and lung tumours. Circles with bars indicate the
mean value and the standard deviation










Figure 4 Southern blot analysis of p73 gene using genomic DNA extracted
from three representative cases in which p73 mRNA in lung cancer tissues
was expressed stronger than in normal lung tissues. (A) Ethidium bromide
stained gel electrophoresis after digestion of 10-mg genomic DNA with
HindIII; (B) Southern blot hybridization with the labelled p73 cDNA probe
(containing exons 5, 6 and a part of exon 7 of p73), which was amplified by
RT-PCR with P1 and P2 as described in Materials and Methods. T, lung
cancer tissue; L, paired normal lung tissue
LTLTLTLTLTLT LTLT
196 200 201 202 203 205 206 208 Case No.
p73 (P1 and P2)
b-actin
A
Bby PCR-SSCP, in exons 4–8 and exon 10, and subsequent direct
sequencing: we found that 43% (21/49) had mutant p53
(Table 1), much the same frequency as in previous reports
(Kishimoto et al, 1992). The mean levels of p73 expression in 21
mutant p53 cases and 28 wild p53 cases are 6.19 and 5.17 respec-
tively, and there was no statistically significant correlation
between  p53 gene alteration and p73 expression (P = 0.11, Table
2). Moreover, even when we divided the subjects into two groups
by histological difference, no association was found between p53
gene alteration and p73 expression.
DISCUSSION
The p53 gene and its protein product have been the centre of inten-
sive cancer studies since more than 50% of human cancers contain
this gene abnormality (Levine, 1997). Because p73 closely resem-
bles p53 in transactivation (29% identity with p53 amino acids),
DNA binding (63% identity with p53), and p53 oligomerization
(38% identity with p53) domains, p73 is thought to play an impor-
tant role in the development and/or progression of various types of
human cancers (Dickman, 1997; Kaghard et al, 1997; Oren, 1997).
In fact, p73 can enhance levels of endogenous p21/Waf1 protein,
the representative target of p53, and p73 can also inhibit cell
growth by inducing apoptosis in a p53-like manner (Jost et al,
1997; Kaghard et al, 1997).
In the present study we clearly showed that levels of p73 mRNA
expression is higher in tumours than in normal tissues, as two
previous papers dealing with only a few samples had reported
(Mai et al, 1998; Takahashi et al, 1998). In four reports the authors
failed to find p73 genomic mutation despite intensive search
(Kaghard et al, 1997; Mai et al, 1998; Nomoto et al, 1998;
Takahashi et al, 1998). Judging from these results, it was possible
that wild-type p73, not mutant p73, might be overexpressed
exclusively in tumours. Furthermore, our results revealed that p73
overexpression was not due to gene amplification but, in all prob-
ability, to induction of transcription or to stabilization of p73
mRNA. Moreover, we showed that p73 overexpression is
independent of p53 gene alteration.
There are two possible explanations of the relationship between
p73 overexpression and lung carcinogenesis. The first is that p73
may work as a security guard (Dickman, 1997): we found no direct
relationship between p53 mutation and p73 overexpression in the
present study, but the cell cycle in cancer cells is generally faster
than in normal cells regardless of p53 gene status, so p73 might
work to arrest the cell cycle as a tumour suppressor gene. The
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Table 2 The relationship between the amount of p73 expression and
clinicopathological features in 53 adenocarcinomas and squamous cell
carcinomas
Clinical features No. of cases p73 : b-actin ratioa P-valueb
Age
<61 26 3.74 ± 3.47 0.018
³61 27 7.91 ± 7.69
Sex
Men 38 6.95 ± 6.93 0.023
Women 15 3.11 ± 3.08
Histology
Adenocarcinoma 34 3.73 ± 3.60 0.001
Squamous cell carcinoma 19 9.68 ± 8.20
p-Stage
I 18 5.01 ± 6.97 0.15
³II 35 6.30 ± 6.00
Smoking index
<400 20 2.80 ± 2.79 0.001
³400 33 7.72 ± 7.12
p53 gene status
Wild 28 5.17 ± 6.49 0.11
Mutant 21 6.19 ± 4.34
aMean ± s.d. bMann–Whitney U-test.
Table 3 Spearman rank correlation coefficients for p73 : b-actin ratio in tumours and clinicopathological characteristics in 53 adenocarcinoma and squamous
cell carcinomas
Sex Age Histology Smoking index p-Stage p73/b-actin ratio
Sex 1.0
Age 0.10 1.0
Histology 0.47a 0.21 1.0
Smoking index 0.75a 0.09 0.38a 1.0
p-Stage 0.02 0.02 0.09 0.08 1.0
p73:b-actin ratio 0.32b 0.40a 0.46b 0.30a 0.10 1.0
aP < 0.01, bP < 0.05.
Table 4 Partial correlation analysis for p73 : b-actin ratio in tumours and clinicopathological characteristics in 53 adenocarcinoma and squamous cell
carcinomas
Partial correlation coefficients Variables under control
Sex 0.05 Age, Histology, Smoking index, p-Stage
Age 0.39a Sex, Histology, Smoking index, p-Stage
Histology 0.34b Sex, Age, Smoking index, p-Stage
Smoking Index 0.04 Sex, Age, Histology, p-Stage
p-Stage –0.05 Sex, Age, Histology, Smoking index
aP < 0.01; bP < 0.05second possibility is that p73 might act as an oncogene in up-regu-
lation of cell growth, as Mai et al (1998) pointed out. Kaghad et al
(1997) reported that p73 protein is neither stabilized nor activated
by DNA damage, including damage from UV radiation or actino-
mycin D, so it is clearly different from p53. Because the expres-
sions of p73 and p53 are induced in different manners, it is
possible that p73 may have a role different from that of p53 in lung
cancer carcinogenesis. And since, in the present study, p73 over-
expression was observed exclusively in lung tumour, p73 may
possibly work as an oncogene in lung carcinogenesis.
In the present study, our results suggest that p73 overexpression
in tumours correlates with histological type and age of patients.
Furthermore, p73 expression in normal lung tissues also correlates
with age of patients, although p73 expression in normal lung
tissues is much lower than that in tumours. Accordingly, p73
expression might be associated with the changes accompanying
aging of the host or differences of histological construction in
tumors. These observation will provide some clue as to why p73 is
overexpressed in lung tumour.
In conclusion, p73 expression in lung tumours is obviously
greater than its expression in normal tissues, independent of p53
gene alteration, indicating that the role of p73 in lung carcino-
genesis might be different from its role in neuroblastoma. Further
study is needed of this possible new function of p73 protein.
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